Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 100 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 100 50.
ENDURONYL vs HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the Na+-Cl− symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis.
Hydralazine: Direct vasodilation of arterioles via unknown mechanism, possibly involving nitric oxide. Hydrochlorothiazide: Thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
ENDURONYL (methyclothiazide and deserpidine) is a fixed-dose combination antihypertensive. Typical adult dose: 1 tablet (methyclothiazide 5 mg / deserpidine 0.25 mg) orally once daily. Dose may be increased to 2 tablets once daily if needed.
1 tablet (hydralazine 100 mg / hydrochlorothiazide 50 mg) orally once daily. Maximum: 1 tablet daily. Titrate from lower doses of individual components.
None Documented
None Documented
Terminal elimination half-life 10-15 hours; clinically, may require 3-5 days to reach steady state in hypertension management.
Hydralazine: 2-8 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (increased in renal impairment)
Primarily renal excretion; ~50% unchanged, ~25% as deserpidine metabolites, 20% biliary-fecal.
Hydralazine: 90% renal metabolites, 10% feces; Hydrochlorothiazide: >95% renal (tubular secretion) as unchanged drug
Category C
Category A/B
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic